Literature DB >> 1536632

Therapy for neurocysticercosis. Comparison between albendazole and praziquantel.

O M Takayanagui1, E Jardim.   

Abstract

Praziquantel and albendazole have been recently described as effective drugs for treatment of intraparenchymal brain cysticercosis. We performed a prospective study comparing the efficacy of these drugs. Twenty-two patients were treated with praziquantel and 21 with albendazole. In addition, 16 patients were treated with symptomatic drugs only and used as controls. Treatment was discontinued in two patients receiving praziquantel and one patient receiving albendazole owing to acute decompensation of the increased intracranial pressure, and one of them died. Albendazole and praziquantel were effective when compared with the control group. However, albendazole was significantly more effective than praziquantel in reducing the total number of cysts in the computed tomographic scans (88% vs 50%). Despite these results, however, analysis of clinical course showed a high frequency of neurologic sequelae. Considering the risks and fallibility of anticysticercal therapy, the real solution for this serious disease continues to be prophylaxis of infestation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1536632     DOI: 10.1001/archneur.1992.00530270106026

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  31 in total

1.  High-dose praziquantel with cimetidine for refractory neurocysticercosis: a case report with clinical and MRI follow-up.

Authors:  T Yee; J A Barakos; R T Knight
Journal:  West J Med       Date:  1999-02

2.  Neurocysticercosis.

Authors:  Oscar H Del Brutto
Journal:  Neurohospitalist       Date:  2014-10

3.  Is the presence of depression independent from signs of disease activity in patients with neurocysticercosis?

Authors:  Sergio Monteiro de Almeida; Solange Aparecida Gurjão
Journal:  J Community Health       Date:  2011-10

4.  Novel inhibitors to Taenia solium Cu/Zn superoxide dismutase identified by virtual screening.

Authors:  P García-Gutiérrez; A Landa-Piedra; A Rodríguez-Romero; R Parra-Unda; A Rojo-Domínguez
Journal:  J Comput Aided Mol Des       Date:  2011-12-04       Impact factor: 3.686

5.  NEUROLOGICAL INFECTIONS IN THE RETURNING INTERNATIONAL TRAVELER.

Authors:  May H Han; Melanie Walker; Joseph R Zunt
Journal:  Continuum (Minneap Minn)       Date:  2006-04

6.  Neurocysticercosis.

Authors:  Vincent C Marconi; Hector H Garcia; Joel T Katz
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

7.  Albendazole in neurocysticercosis.

Authors:  D Kapil; P Vohra
Journal:  Indian J Pediatr       Date:  1993 Jan-Feb       Impact factor: 1.967

8.  Solitary cysticercosis of the biceps brachii in a vegetarian: a rare and unusual pseudotumor.

Authors:  Ibrahim Fikry Abdelwahab; Michael J Klein; George Hermann; Mohammed Abdul-Quader
Journal:  Skeletal Radiol       Date:  2003-05-03       Impact factor: 2.199

9.  Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis.

Authors:  O M Takayanagui; P S Bonato; S A C Dreossi; V L Lanchote
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

10.  Diagnosis and treatment of neurocysticercosis.

Authors:  Christina M Coyle; Herbert B Tanowitz
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.